Compare McKesson Corporation (MCK) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Standard Lithium Ltd — how do they compare? McKesson Corporation trades at $832.45 (market cap $97.35B), while Standard Lithium Ltd trades at $2.27 (market cap $523.89M). The key difference: McKesson Corporation is far larger — about 185.8× Standard Lithium Ltd's market cap, and McKesson Corporation pays a 0.39% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| MCK | SLI | |
|---|---|---|
Market Cap | $97.35B | $523.89M |
Sector | Health | Basic Materials |
52-Week High | $995.69 | $5.65 |
52-Week Low | $659.01 | $2.15 |
Enterprise Value | $101.98B | $383.09M |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
Standard Lithium (SLI) trades at $2.15, down 4.87% today, reflecting ongoing bearish technical momentum despite a 100% buy rating from 3 analysts. The stock shows negative profitability with ROE at -16.6% and net income of -$48.40M in 2025, though recent Q1 2026 earnings beat expectations. Key developments include progress on its Arkansas lithium project, a $225M DOE grant, and a binding offtake agreement with Trafigura, positioning the company for future production by 2029.
The investment case hinges on successful project execution and lithium market dynamics, offering high growth potential but carrying significant operational and funding risks. Current negative cash flows and reliance on financing highlight volatility, making it suitable for risk-tolerant investors betting on the energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
